Leading Independent Advisory Firm Institutional Shareholder Services, Inc. Recommends Baudax Bio Shareholders Vote “For” the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders

Jun 30, 2021 7:00am EDT

Baudax Bio Announces Special Meeting of Shareholders to Vote on Proposed Increase in Number of Authorized Shares of Common Stock

Jun 18, 2021 4:05pm EDT

Baudax Bio to Participate in the JMP Securities Life Sciences Conference

Jun 10, 2021 7:00am EDT

Baudax Bio’s ANJESO® Achieves Formulary Listing at Over 100 Institutions in Less Than One Year on the Market

Jun 08, 2021 7:00am EDT

Baudax Bio Announces $11.9 Million Registered Direct Offering

May 31, 2021 10:56pm EDT

Baudax Bio Announces the Cancellation of Adjourned Portion of Annual Shareholder Meeting

May 28, 2021 4:05pm EDT

Baudax Bio to Present at the 2021 Jefferies Virtual Healthcare Conference

May 27, 2021 7:00am EDT

Baudax Bio Announces Publication of Phase IIIb ANJESO® Data in the Journal Pain Management

May 17, 2021 7:00am EDT

Leading Independent Advisory Firm Institutional Shareholder Services, Inc. Recommends Baudax Bio Shareholders Vote "For" the Proposed Additional Authorized Shares

May 13, 2021 7:00am EDT

Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends Baudax Bio Shareholders Vote "For" The Additional Authorized Shares

May 12, 2021 9:02am EDT